Lifestyle
- Regular physical activity
- Weight management
- Stress reduction
C-Peptide · Connecting Peptide
C-Peptide quantifies the amount of insulin produced endogenously by the pancreas.
Fasting sample preferred; renal function can affect levels.
C-Peptide, also known as Connecting Peptide, is a short polypeptide that connects the A and B chains of insulin in its proinsulin form. It is released into the bloodstream in equimolar amounts to insulin during the conversion of proinsulin to insulin, making it a useful marker for endogenous insulin production. Researchers have found that C-Peptide reflects beta-cell function and can be used to differentiate between types of diabetes, particularly in distinguishing type 1 from type 2 diabetes. Clinically, C-Peptide is important for assessing residual beta-cell function in diabetes management. Elevated levels may indicate insulin resistance or insulinoma, while low levels are often seen in type 1 diabetes due to autoimmune destruction of beta cells. In the context of athletic performance and biohacking, C-Peptide levels can provide insights into metabolic health and insulin sensitivity, which are crucial for optimizing energy utilization and recovery. However, the interpretation of C-Peptide levels can be confounded by factors such as renal function, as C-Peptide is cleared by the kidneys, and assay standardization issues. Time-of-day and fasting status can also influence measurements, necessitating standardized testing conditions to ensure accuracy.
Klinische Bedeutung
Elevated C-Peptide levels may indicate insulin resistance, insulinoma, or type 2 diabetes. Reduced levels are typically associated with type 1 diabetes or advanced type 2 diabetes with significant beta-cell dysfunction.
Progressively rising C-Peptide levels suggest increasing insulin resistance or possible insulinoma. Re-test in 3-6 months if clinically indicated.
Progressively falling levels may indicate worsening beta-cell function, particularly in type 1 diabetes.
Re-test Interval
6 months if outside optimal range
Note:
Consult physician before making significant lifestyle changes, especially if diabetic.
Testing Frequency
Annually for diabetes management or as directed by a healthcare provider.
Directly measures
Current research suggests that the clinical utility of C-peptide measurement in type 2 diabetes remains debated due to confounding factors like insulin resistance and the lack of standardized assays across laboratories. Researchers have not yet established optimal reference ranges or targets for C-peptide in diabetes management. Additionally, unanswered clinical questions include the precise role of C-peptide in differentiating diabetes types and its potential therapeutic applications in preventing end-organ damage.
613
Total Citations
5
Human/RCT
6.0
Avg. Influence
2024
Latest
This study examined guidelines for laboratory analysis in diagnosing and managing diabetes mellitus. Researchers found that various tests, including C-peptide measurement, can assist in understanding diabetes but some analytes have limited clinical value at present. The study emphasizes the need for evidence-based recommendations for effective diabetes management.
This review focused on proinsulin and C-peptide, highlighting their roles in insulin synthesis. Researchers found that while proinsulin has some biological activity, C-peptide is biologically inert. Advances in measurement techniques have improved the assessment of C-peptide in clinical settings.
This study explored the role of C-peptide in diagnosing and managing different types of diabetes. Researchers found that C-peptide levels reflect beta-cell function, aiding in diabetes classification and treatment decisions. However, the clinical utility of C-peptide in type 2 diabetes is limited due to insulin resistance and assay standardization issues.
This study reiterated the importance of laboratory tests in diabetes management, including C-peptide measurement. Researchers found that while some tests are valuable, others are not recommended due to minimal clinical utility. The guidelines aim to provide clear recommendations for effective diabetes diagnosis and monitoring.
This study provided evidence for using C-peptide as a biomarker in type 1 diabetes clinical trials. Researchers found that C-peptide levels correlate with β-cell function and clinical outcomes, suggesting its potential as a meaningful measure for evaluating new therapies.
This study evaluated how hemolysis, lipemia, and icterus affect clinical immunoassays, including C-peptide measurements. Researchers found that C-peptide levels can be significantly impacted by hemolysis, leading to potential inaccuracies in results. The study highlights the importance of understanding these interferences for accurate laboratory testing.
This study investigated the multifunctional role of C-peptide in diabetes. Researchers found that C-peptide has protective effects in early diabetes stages but may promote complications in late stages. This dual role suggests C-peptide could be a valuable biomarker for understanding diabetes progression.
This study examined the potential of C-peptide testing for early diagnosis of gestational diabetes. Researchers found that elevated C-peptide levels in early pregnancy could indicate a higher risk of developing gestational diabetes, suggesting a need for preventive strategies.
This study assessed the interlaboratory comparability of C-peptide measurements using LC-MS/MS. Researchers found that the method demonstrated high precision and linearity, suggesting it could improve standardization in diabetes research and patient care.
This study examined the impact of hemolysis on C-peptide immunoassays. Researchers found that hemolysis negatively affects C-peptide measurement accuracy and developed a correction equation to improve result reliability. This advancement aims to enhance diagnostic accuracy in clinical practice.
Research publications about C-Peptid over time
9totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer